ABL Bio에이비엘바이오
298380 · KOSDAQ · ₩298380 · 에이비엘바이오
₩41,000▼ ₩800 (1.91%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩79B | ₩33B | ₩66B | ₩67B | ₩5.3B |
| Operating income | −₩40B | −₩59B | −₩2.6B | ₩908M | −₩52B |
| Net income | −₩38B | −₩56B | −₩2.6B | ₩3.2B | −₩44B |
| Net income to shareholders | −₩38B | −₩56B | −₩2.6B | ₩3.2B | −₩44B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩281B | ₩232B | ₩160B | ₩185B | ₩65B |
| Current assets | ₩176B | ₩144B | ₩76B | ₩81B | ₩45B |
| Cash and equivalents | ₩112B | ₩56B | ₩28B | ₩25B | ₩22B |
| Total liabilities | ₩124B | ₩65B | ₩86B | ₩116B | ₩9.5B |
| Current liabilities | ₩123B | ₩63B | ₩42B | ₩72B | ₩8.8B |
| Borrowings | ₩55B | — | — | — | ₩6.2B |
| Total equity | ₩157B | ₩167B | ₩74B | ₩70B | ₩56B |
| Shareholders' equity | ₩155B | ₩167B | ₩74B | ₩70B | ₩56B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩41B | −₩69B | −₩28B | ₩72B | −₩41B |
| Free cash flow | −₩41B | −₩69B | −₩28B | ₩72B | −₩41B |
Consolidated where available. Amounts in won.
Also known as: ABL Bio / 에이비엘바이오 / 298380 / KRX:298380
Source: KRX statistical information